GT Biopharma

GT Biopharma (NASDAQ: GTBP) is a clinical-stage immuno-oncology company headquartered in San Francisco, California, developing natural killer (NK) cell engager therapeutics built on its Tri-specific Killer Engager (TriKE) and dual-targeting Tetra-specific Killer Engager platforms. Its lead program, GTB-3650, is in Phase 1 development against CD33-expressing myeloid leukemias; GTB-5550 is in a Phase 1 dose-escalation basket trial in B7-H3-positive advanced solid tumors; and GTB-7550 is a preclinical candidate for lupus and other autoimmune disorders. The company was incorporated in 1965, was formerly known as OXIS International, and adopted the GT Biopharma name in July 2017. On September 11, 2026, shares rose 39.32% on volume 11.49 times the 30-day average as the company hosted a live presentation on the TriKE platform and its clinical progress, against roughly $5.1 million of cash and equivalents at June 30, 2026 and company guidance that runway extends through the fourth quarter of 2026.